Ramipril - Hypertension

Phase 4 Completed 1008 enrolled Sanofi

RandomizedParallel-groupOpen-labelTreatment

Summary

Primary objective: Mean values of systolic and diastolic office blood pressure Secondary objectives: Total mortality, occurrence of cardio- and cerebrovascular events, change of mean blood pressure (ABPM : Ambulatory Blood Pressure Monitoring) during the observation

Timeline

Start: 2000-05
Primary completion: 2005-08
Completion: 2005-08

Outcome

Met primary endpoint

paper One hundred and fifty-five patients (30.7%) in the ramipril group, and 216 (42.9%) in the control group reached the primary endpoint PMID 18551027 ↗

paper reached the primary endpoint (relative risk reduction 34.4%, P = 0.0001). PMID 18551027 ↗

Publications

Results Luders S, Schrader J, Berger J, Unger T, Zidek W, Bohm M, Middeke M, Motz W, Lubcke C, Gansz A, Brokamp L, Schmieder RE, Trenkwalder P, Haller H, Dominiak P; PHARAO Study Group. The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League. J Hypertens. 2008 Jul;26(7):1487-96. doi: 10.1097/HJH.0b013e3282ff8864.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ramipril	Small molecule	—	—